Brain Tumor News!

Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!

06/27/10 The remarkable story of Virtualtrials.com        

06/24/10 Radiation Errors Reported in Missouri        

06/23/10 IsoRay and Hologic Sign Exclusive Worldwide License for Crucial Brain Cancer Treatment Device FDA-Cleared GliaSite(R) Balloon Catheter Is World's Only Device to Deliver Liquid Radiation Source Therapy        

06/19/10 Please vote for Musella Foundation! Help us win contest!        

06/18/10 Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?        

06/16/10 Is Northwest Biotherapeutics (OTC:NWBO) Ready To Mount A Comeback?        

06/11/10 ImmunoCellular Drug Granted Orphan Drug Status        

06/08/10 Fast track, "compassionate use," FDA approval bill for terminal patients filed.        

06/08/10 FDA approves first human neural stem cell clinical trial to treat brain tumors        

06/08/10 NovoTTF-100A improved response, time to treatment failure in recurrent glioblastoma        

06/08/10 Brain cancer vaccine shows promise        

06/08/10 BRAIN: 16% of patients with relapsed glioblastoma alive at 30 months (Avastin)        

06/08/10 Exceptional Survival Data, Lower Costs Key to the Competitive Advantage of DCVax(R) - Northwest Biotherapeutics' Vaccine for Multiple Cancers        

06/08/10 Reradiating Recurrent Gliomas Is Effective, Well-Tolerated        

06/07/10 Children's Memorial Hospital, Chicago, First Children's Hospital in Illinois to Acquire New Device for Pediatric Brain and Spine Tumor Removal        

06/07/10 Initial Experience Involving Treatment and Retreatment With Carmustine Wafers in Combination With Oral Temozolomide: Long-term Survival in a Child With Re lapsed Glioblastoma Multiforme.        

06/07/10 Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.        

06/05/10 Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual ASCO Meeting        

06/05/10 Cilengitide Study Provides Long-Term Follow-up Data in Glioblastoma Patients Receiving Investigational Drug for More Than 4 Years        

---

Displaying Stories 3090 to 3109 of 7806
Previous 20           Next 20